Clinical trials
Recent articles
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
Going against the gut: Q&A with Kevin Mitchell on the autism-microbiome theory
A new review of 15 years of studies on the connection between the microbiome and autism reveals widespread statistical and conceptual errors.
Going against the gut: Q&A with Kevin Mitchell on the autism-microbiome theory
A new review of 15 years of studies on the connection between the microbiome and autism reveals widespread statistical and conceptual errors.
Why we need basic science to better understand the neurobiology of psychedelics
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering questions.
Why we need basic science to better understand the neurobiology of psychedelics
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering questions.
Why hype for autism stem cell therapies continues despite dead ends
After numerous tests, there is still no evidence that these experimental treatments help, so now is not the time to expand access to them.
Why hype for autism stem cell therapies continues despite dead ends
After numerous tests, there is still no evidence that these experimental treatments help, so now is not the time to expand access to them.
Expediting clinical trials for profound autism: Q&A with Matthew State
Aligning Research to Impact Autism, a new initiative funded by the Sergey Brin Family Foundation, wants to bring basic science discoveries to the clinic faster.
Expediting clinical trials for profound autism: Q&A with Matthew State
Aligning Research to Impact Autism, a new initiative funded by the Sergey Brin Family Foundation, wants to bring basic science discoveries to the clinic faster.
What’s next for brain-directed gene therapy after death in Neurogene trial
The incident highlights that viral vectors can trigger deadly immune responses even when delivered directly to the nervous system.
What’s next for brain-directed gene therapy after death in Neurogene trial
The incident highlights that viral vectors can trigger deadly immune responses even when delivered directly to the nervous system.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Leveraging the power of community to strengthen clinical trials for rare genetic syndromes
Families can become not only participants but champions of these research efforts.
Leveraging the power of community to strengthen clinical trials for rare genetic syndromes
Families can become not only participants but champions of these research efforts.
Explore more from The Transmitter
An Iranian, an Israeli, and a Palestinian neuroscientist walked into a bar…
That chance occurrence at an SfN social led us to organize the Middle Eastern Systems Neuroscience Symposium, and forge a plan to build a community that transcends political barriers through scientific connection.
An Iranian, an Israeli, and a Palestinian neuroscientist walked into a bar…
That chance occurrence at an SfN social led us to organize the Middle Eastern Systems Neuroscience Symposium, and forge a plan to build a community that transcends political barriers through scientific connection.
Federal advisory panel extends comment period, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 27 July.
Federal advisory panel extends comment period, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 27 July.
Oregon primate research center to downsize monkey colony, pivot to non-animal models
The center’s host university had been negotiating with the federal government about converting the center into an animal sanctuary. A new plan, approved today, preserves some of the center’s nonhuman primate studies.
Oregon primate research center to downsize monkey colony, pivot to non-animal models
The center’s host university had been negotiating with the federal government about converting the center into an animal sanctuary. A new plan, approved today, preserves some of the center’s nonhuman primate studies.